

Strategies to Better Align Investments in Innovations for Therapeutic Development with Disease Burden and Unmet Needs Meeting 4

PUBLIC SPEAKER AGENDA

[CLICK FOR SPEAKER
SESSION](#)

TUESDAY, OCTOBER 1, 2024

- | | |
|----------------|---|
| 1:00 PM | Welcome and Introduction to the Study
Don Berwick , Committee Co-Chair |
| 1:05 PM | Presentation
Patrizia Cavazzoni , Center for Drug Evaluation and Research, U.S. Food and Drug Administration |
| 1:25 PM | Discussion
Stacey Adam , Committee Member and Moderator |
| 1:55 PM | Closing Remarks
Adjourn |

Strategies to Better Align Investments in Innovations for Therapeutic Development with Disease Burden and Unmet Needs Meeting 4

Speaker Biography

Patrizia Cavazzoni, M.D

Patrizia Cavazzoni, M.D., is the director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration.

Dr. Cavazzoni received her medical degree from McGill University and completed a residency in psychiatry and a fellowship in mood disorders at the University of Ottawa. She subsequently joined the Faculty of Medicine at the University of Ottawa as an Assistant Professor in Psychiatry.

After her tenure in academic medicine, Dr. Cavazzoni worked in the pharmaceutical industry for several years and held senior executive positions in clinical development, regulatory affairs, and safety risk management across multiple therapeutic areas, until she joined the FDA in January 2018.

Moderator Biography

Stacey Adam, PhD

Stacey Adam, PhD, is an Vice President at the FNIH, leading many public-private partnerships, such as Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV); the Biomarkers Consortium (Cancer and Metabolic Disorders Steering Committees) and their projects; Accelerating Medicines Partnerships (AMPs)-Common Metabolic Diseases and Heart Failure; Pediatric Medical Devices PPP; Partnership for Accelerating Cancer Therapies (PACT); and the Lung Master protocol (Lung-MAP) clinical trial.

Prior to FNIH, Dr. Adam was a Manager at Deloitte Consulting in the Federal Life Sciences and Healthcare Strategy practice where she supported many federal and non-profit client projects. Before Deloitte, Dr. Adam conducted her postdoctoral fellowship at Stanford University School of Medicine, where she was both an NIH and American Cancer Society supported fellow, and she earned her Ph.D. in Pharmacology with a Certificate in Mammalian Toxicology from Duke University. She did her BS in Medical Technology/Clinical Laboratory Science from University of Nebraska-Medical Center and graduated Sigma Cum Laude.

Dr. Adam is a member of the American Associate of Cancer Research and the American Society of Clinical Oncology. She has received the NIH Directors Award four times between 2020-2022 for her work on the partnerships with NIH.